Dr. Agarwal's Health Care Ltd. (AGARWALEYE) — Tipsheet

Dr. Agarwal's Health Care Q4 transcript adds no new data

Tipsheet Editorial — Wed, 27 May 2026 13:46:05 GMT

The company's latest earnings call transcript recaps previously disclosed financial results and provides standard updates on the merger process.

What’s new

The Q4 FY26 earnings call transcript contains no new financial figures.
Management provided standard updates on the ongoing merger process.
The session recapped previously disclosed results and commentary.

Why it matters

The transcript is a procedural document. It adds no fresh information for investors. It is a record of management's commentary rather than a source of new material facts.

What we’re watching

Future regulatory updates regarding the merger timeline.
Actual financial performance in upcoming quarterly filings.
Management's ability to integrate operations post-merger.

The full read

Dr. Agarwal's Health Care released the transcript for its Q4 FY26 earnings call held on May 21, 2026. The document records management's commentary and the subsequent Q&A session. It covers previously disclosed financial results and offers standard updates regarding the company's ongoing merger process. The filing contains no new material data or surprising information that would alter current market expectations. It is a routine summary of known developments.

Primary source: BSE · NSE

Dr. Agarwal's Health Care reports FY26 revenue of over ₹2,000 cr

Tipsheet Editorial — Thu, 21 May 2026 19:56:07 GMT

The company confirms FY26 growth targets with plans to add 60 new facilities in FY27 at a cost of up to ₹400 cr.

What’s new

The concall summary recaps FY26 results with revenue growth of 20.9% and PAT growth of 52.4%.
Management plans to add 60 new facilities in FY27.
Capex for FY27 is projected between ₹380 cr and ₹400 cr, with EBITDA margins seen at 28-30%.

Why it matters

The conference call confirms the financial trajectory and expansion plans already communicated in previous disclosures. No new material information emerged from the discussion.

What we’re watching

Execution of the 60-facility expansion plan in FY27.
Consistency of EBITDA margins within the 28-30% range.
Actual deployment of the projected ₹380-400 cr capex.

The full read

Dr. Agarwal's Health Care closed FY26 with revenue topping ₹2,000 crore, representing a 20.9% increase over the previous year. Profit after tax grew by 52.4% as the company maintained its expansion pace. Management used the earnings call to reconfirm the outlook for FY27, which includes opening 60 new facilities supported by a capital expenditure budget of ₹380 crore to ₹400 crore. The company anticipates EBITDA margins will remain steady between 28% and 30%. Because these details were already contained in prior filings, the call provides no new market-moving data. It serves merely as a formal walkthrough of results already priced into the equity.

Primary source: BSE · NSE

Dr. Agarwal's profit jumps 52% on 21% revenue growth

Tipsheet Editorial — Thu, 21 May 2026 18:22:29 GMT

Same-store sales rose 14% as the eye-care chain adds 57 facilities and plans 60 more in FY27.

What’s new

FY26 total income rose 20.9% to ₹2,125 crore; net profit surged 52.4% to ₹168 crore.
The company added 57 eye-care facilities, ending the year with 288 centres in 155 Indian cities.
Plans to open 60 new facilities in FY27, with 40 being surgical centres, and a rising share in northern and eastern India.

Why it matters

The profit growth outpacing revenue points to improving margins as the network matures. The detailed presentation adds granular operational data, like 14.1% same-store sales growth, that wasn't in the pre-announced headline numbers. The explicit plan to open 40 surgical centres next year is a clear signal toward higher-margin procedures.

What we’re watching

Whether 14.1% same-store growth holds as the network densifies.
Execution of the 40 surgical-centre rollout in FY27.
The pace of market share gains in northern and eastern India.

The full read

Dr. Agarwal's Health Care's FY26 numbers are strong. Total income hit ₹2,125 crore, up 20.9%. Net profit leapt 52.4% to ₹168 crore. The investor presentation matters not for the headline figures, but for the operational detail underneath. Same-store sales grew 14.1%, proving the existing 288 centres are productive, not just expanding. That expansion continues at pace. The company added 57 facilities last year. The plan for FY27 is 60 more, with 40 being surgical centres. That's a strategic bet on higher-margin work. Profit growing more than twice as fast as revenue confirms the model is scaling. The next test is whether the surgical-centre push and expansion into northern and eastern India can sustain that margin trajectory.

Primary source: BSE · NSE

Dr. Agarwal's Health Care lifts PAT 52% on 22% revenue growth

Tipsheet Editorial — Thu, 21 May 2026 18:13:38 GMT

Strong FY26 numbers across the board, but a routine earnings release with an immaterial IPO expense reallocation. Growth was likely guided.

What’s new

Revenue up 21.6% YoY; EBITDA up 22.2%.
PAT surges 52.4% YoY – the standout metric.
Board reallocates ₹14.88 cr of unspent IPO expenses – 0.1% of market cap.

Why it matters

The earnings are strong, but the filing is standard and the numbers were within prior guidance. The real question is whether this growth rate can sustain into FY27 without fiscal tailwinds.

What we’re watching

FY27 guidance – can revenue growth stay above 20%?
Any expansion plans or new hospital additions.
Competitive pressure from other eye care chains.

The full read

Dr. Agarwal's Health Care closed FY26 with solid momentum: revenue climbed 21.6%, EBITDA 22.2%, and PAT jumped 52.4% – all year-on-year. The earnings release itself is routine, and the sole non-operating item – a ₹14.88 crore reallocation of unspent IPO proceeds – is negligible at 0.1% of market cap. The market likely had these numbers in mind after prior guidance and industry trends. So the filing confirms good performance but adds little new. The focus shifts to whether Dr. Agarwal can repeat this pace, especially as the base effects roll off.

Primary source: BSE · NSE

Dr. Agarwal's Q4 profit jumps 52%, but the numbers were already priced in.

Tipsheet Editorial — Thu, 21 May 2026 18:08:44 GMT

Consolidated PAT hit ₹168 cr in Q4, a 52.4% YoY jump. Total income for the quarter was ₹2,125 cr.

What’s new

Q4 consolidated PAT rose 52.4% YoY to ₹168 cr, outpacing both revenue and EBITDA growth.
FY26 total income hit ₹2,125 cr, up 20.9% YoY; EBITDA grew 22.2% to ₹614 cr.
Board approved shifting ₹14.88 cr in unspent IPO expenses to general corporate purposes.

Why it matters

The 52.4% profit surge is sharp, but it's largely a low-base effect from the prior-year quarter. The ₹14.88 crore in unspent IPO money being freed for inorganic moves is a procedural signal, not a material shift for a company with a ₹14,997 crore market cap.

What we’re watching

Whether the company announces its first inorganic deal using the reallocated IPO funds.
How the profit growth translates in FY27, now that the low base fades.
Any update on the margin trajectory, given the divergence between revenue (20.9%) and PAT (52.4%) growth.

The full read

Dr. Agarwal's Health Care posted a Q4 profit of ₹168 crore, up 52.4% year-on-year. Revenue grew 20.9% to ₹2,125 crore for the full year, while EBITDA climbed 22.2% to ₹614 crore. The profit surge outpaces the top line, pointing to operating effects from the company's model. But the numbers were expected. For a ₹14,997 crore market-cap company, the real move is small: ₹14.88 crore in unspent IPO expenses are now freed up for inorganic bets. That's a tiny war chest, but it's the first public signal the company is ready to buy.

Primary source: BSE · NSE